All Things Insulin: Dosing, Monitoring, Titrating, and Transitioning


New and emerging insulin products not only expand therapeutic options but also complicate treatment decisions for parents, prescribers, and pharmacists. Newer agents include insulin glargine U300, regular insulin U500, and insulin degludec U-100 and U-200. In this interactive case-based session, experts will facilitate a discussion about the safe and effective use of new insulin products including strategies to titrate insulin doses, methods to safely switch insulin products, and practical advice to minimize hypoglycemia.

Pharmacist Learning Objectives

At the completion of this application-based activity, participants will be able to:

  1. Compare the characteristics of new insulin agents available in the market.
  2. Explain the potential roles of recently approved insulins in the management of type 1 and type 2 diabetes.
  3. Describe strategies to minimize insulin-induced hypoglycemia, including patient education tools.
  4. Demonstrate how to safely switch patients among available insulin products.
  5. Discuss management strategies when switching patients to insulin U500.


This activity is supported by independent educational grants from Novo Nordisk, Inc., Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Stuart Haines, PHARMD
Professor and Director, Pharmacy Professional Development
University of Mississippi School of Pharmacy
Jennifer Trujillo,
University of Colorado Denver
Learning Level: Level 2
Track: Clinical Patient Care and Services
Session Time Slot(s): 
Monday, March 19
10:00 AM - 12:00 PM
Music City Center - Room 104A-B
ACPE Pharmacist: 0202-0000-18-052-L01-P
CEUs Pharmacist: 0.2
Activity Type: